IKEM
[redacted]
M16-000

TERMINATION LETTER FOR CLINICAL STUDY AGREEMENT

18 December 2019

Institut klinické a experimentální medicíny
[redacted]
Vídeňská 1958/9
140 21 Praha 4 - Krč
Česká republika

Re: Clinical Study pertaining to **Protocol No. M16-000** entitled "***A Multicenter Randomized, Double-Blind, Placebo-Controlled 52-Week Maintenance and an Open-Label Extension Study of the Efficacy and Safety of Risankizumab in Subjects with Crohn's Disease Who Responded to Induction Treatment in M16-006 or M15-991***" ("Study")

Dea[redacted]

As per mutual conclusion, this letter will serve to terminate the Clinical Study Agreement (the "**Agreement**"), effective 12 April 2018 between **Institut klinické a experimentální medicíny**, Vídeňská 1958/9, 140 21 Praha 4 - Krč, Czech Republic, ID: 000 23 001, VAT ID: CZ00023001, represented by Ing. Michal Stiborek, MBA, Director (the "**Institution**") and **AbbVie, s.r.o.**, Metronom Business Center, Bucharova 2817/13, Stodůlky, 158 00 Praha 5, Czech Republic, ID: 24148725, VAT ID: CZ24148725, represented by [redacted]Country Clinical Operations Manager, based upon power of attorney ("**AbbVie**"), in accordance with Section 12 of the Agreement. Termination shall be effective as of 15 November 2019.

The parties agree to the financial reconciliation attached hereto as **Exhibit A** for the payment of all services performed under the Agreement through the termination date specified above, and as a result

the parties agree that all amounts due under the Agreement through the termination date specified above have been paid in full.

Nothing contained herein shall release the parties from their obligations with respect to any provision of the Agreement, which by their terms survive termination of the Agreement, including but not limited to obligations relating to confidentiality, publication, intellectual property ownership and publicity.

Pursuant to Section 3. Study Materials; Licenses; Equipment, par. e) of the Agreement, AbbVie will make arrangements with Institution for the return of AbbVie's information, including but not limited to the final LEC report on the Study prepared by the Principal Investigator, as well as all completed, used and unused CRFs not already delivered to AbbVie, and all data, reports and other information generated in relation to the Study, as well as all other materials and information provided by AbbVie.

Please refer to the Agreement for any additional obligations of Institution upon termination of the Agreement.

Please acknowledge your receipt of this letter and agreement to the financial reconciliation set forth in this letter by signing and dating this letter and returning one to

[redacted]
M16-000

AbbVie s.r.o.
[redacted]
Country Clinical Operations Manager
Metronom Business Center,
Bucharova 2817/13,
Stodůlky,
158 00 Praha 5
Czech Republic

Very truly yours,

AGREED

AbbVie s.r.o.

By/Podepsal: [redacted]

Name/Jméno: [redacted]

Title/Funkce: Country Clinical Operations Manager upon power of attorney / na základě plné moci

18 -12- 2019

Date/Datum: _____

ACCEPTED

Institut klinické a experimentální medicíny

[redacted]

By/Podepsal: _____

Name/Jméno: **Ing. Michal Stiborek, MBA**

Title/Funkce: Director / ředitel

13. 03. 2020

Date/Datum: _____

[redacted]

By/Pode

Name/J

Title/Funkce: Principal Investigator / Hlavní zkoušející

Date/Datum: 20- JAN - 2020